Abstract
Approximately 5.7 million people died from stroke in 2005 [1]. According to World Health Organization estimates, figures are predicted to increase to 23 million first-ever strokes, 77 million stroke survivors, 61 million disability adjusted life years (DALYs) and 7.8 million deaths in the next 20 years [2]. Heart disease and stroke are leading causes of DALYs lost and deaths worldwide [3]. Over 70 % of ischemic strokes are first events, which makes primary prevention immensely important. The treatments for acute ischemic stroke have emerged during the last decade and there is growing evidence of efficacy and importance of secondary prevention. We foresee that patients at high risk of vascular events could reduce their risk by 75 to 80 % through optimal prevention strategies including a combination of lifestyle changes and medical therapy [4]. In this review, we will focus on the aspects of antithrombotic treatment of ischemic stroke (IS) in the primary and secondary prevention.
Keywords: Stroke, cerebral infarction, antiplatelet medication, antithrombotics, anticoagulants, aspirin, warfarin, prevention
Current Drug Targets
Title: Antithrombotic Treatment in the Prevention of Ischemic Stroke
Volume: 8 Issue: 7
Author(s): Ufuk Emre, Kirsi Rantanen and Turgut Tatlisumak
Affiliation:
Keywords: Stroke, cerebral infarction, antiplatelet medication, antithrombotics, anticoagulants, aspirin, warfarin, prevention
Abstract: Approximately 5.7 million people died from stroke in 2005 [1]. According to World Health Organization estimates, figures are predicted to increase to 23 million first-ever strokes, 77 million stroke survivors, 61 million disability adjusted life years (DALYs) and 7.8 million deaths in the next 20 years [2]. Heart disease and stroke are leading causes of DALYs lost and deaths worldwide [3]. Over 70 % of ischemic strokes are first events, which makes primary prevention immensely important. The treatments for acute ischemic stroke have emerged during the last decade and there is growing evidence of efficacy and importance of secondary prevention. We foresee that patients at high risk of vascular events could reduce their risk by 75 to 80 % through optimal prevention strategies including a combination of lifestyle changes and medical therapy [4]. In this review, we will focus on the aspects of antithrombotic treatment of ischemic stroke (IS) in the primary and secondary prevention.
Export Options
About this article
Cite this article as:
Ufuk Emre , Kirsi Rantanen and Turgut Tatlisumak , Antithrombotic Treatment in the Prevention of Ischemic Stroke, Current Drug Targets 2007; 8 (7) . https://dx.doi.org/10.2174/138945007781077409
DOI https://dx.doi.org/10.2174/138945007781077409 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Developments in the Synthesis of Acetylcholinesterase Inhibitors
Mini-Reviews in Medicinal Chemistry Neutrophil to Lymphocyte (N/L) and Platelet to Lymphocyte (P/L) Ratios in Differentiating Acute Heart Failure from Respiratory Infection
Current Vascular Pharmacology Analysis of Homocysteine in Plasma of Rats Exposed to High-fat Diet and Chronic Unpredictable Mild Stress by LC/ESI-MS/MS
Current Analytical Chemistry Single Photon Emission Tomography in the Diagnostic Assessment of Cardiac and Vascular Infectious Diseases
Current Radiopharmaceuticals Role of Gap Junction Channel in the Development of Beat-to-Beat Action Potential Repolarization Variability and Arrhythmias
Current Pharmaceutical Design Stress and Physical Inactivity: Two Explosive Ingredients for the Heart in COVID-19 Pandemic Times
Current Cardiology Reviews The Role of Integrin-Mediated Cell Adhesion in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Pharmaceutical Design The Effect of Sex and Gender on Diabetic Complications
Current Diabetes Reviews Association Between Chlamydia pneumoniae Antibodies and Lung Cancer: A Meta-Analysis
Current Respiratory Medicine Reviews Polyphenols: A Nutraceutical Approach Against Diseases
Recent Patents on Food, Nutrition & Agriculture Anti-Thrombotic Properties of Tomato
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Role of COX-2 in Heart Pathology
Cardiovascular & Hematological Agents in Medicinal Chemistry Peripartum Cardiomyopathy: An Intensivist's Perspective
Current Women`s Health Reviews Infants and Children with Tachycardia: Natural History and Drug Administration
Current Pharmaceutical Design Cardiac Dys-Synchronization and Arrhythmia in Hyperhomocysteinemia
Current Neurovascular Research A Brief History of ‘Lone’ Atrial Fibrillation: From ‘A Peculiar Pulse Irregularity’ to a Modern Public Health Concern
Current Pharmaceutical Design Recent Strategies Combining Biomaterials and Stem Cells for Bone, Liver and Skin Regeneration
Current Stem Cell Research & Therapy “Cardiovascular” Drugs in Rheumatoid Arthritis: Killing Two Birds with One Stone?
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Biomarkers of Atrial Fibrillation in Metabolic Syndrome
Current Medicinal Chemistry Insights into Immunophilin Structure and Function
Current Medicinal Chemistry